Epinoma

Epinoma is a private, pre-revenue platform company developing EpiAmp, a novel, conversion-free technology for methyl-preserving DNA amplification. This core chemistry is designed to significantly improve the sensitivity and simplicity of epigenetic analysis, particularly for DNA methylation, which is implicated in cancer and neurodegenerative diseases. The company's platform targets applications in precision diagnostics, epi-therapeutics discovery, and biopharma R&D acceleration. Epinoma appears to be in the technology development and early partnership stage, supported by undisclosed investors.

EpiAmp: A conversion-free, methyl-preserving DNA amplification chemistry designed for high-sensitivity analysis of epigenetic markers, enabling single-day, multiplexed workflows.

Epinoma competes in the DNA methylation analysis space against established methods like bisulfite sequencing (Illumina, Qiagen) and newer enzymatic conversion technologies from companies like New England Biolabs and Roche. It also faces competition from long-read sequencing platforms (PacBio, Oxford Nanopore) that can detect methylation natively. Success requires demonstrating clear superiority in sensitivity, simplicity, and cost.